We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Zoll Medical

Develops and markets medical devices and software solutions for advance emergency care, including products for defib... read more Featured Products: More products

Download Mobile App




Wearable Defibrillator Reduces Mortality after Heart Attack

By HospiMedica International staff writers
Posted on 21 Mar 2018
A defibrillator vest allows physicians time to assess and optimize medical therapy, and protects patients at risk for sudden cardiac arrest (SCA).

The Zoll Medical (Chelmsford, MA, US) LifeVest Wearable Cardioverter Defibrillator (WCD) is a lightweight vest (worn under clothing) that continuously monitors a patient’s heart with dry, non-adhesive sensing electrodes; if a life-threatening heart rhythm is detected, the device alerts the patient prior to delivering a treatment shock, allowing a conscious patient to delay treatment. More...
If the patient becomes unconscious, the device releases a special gel over the therapy electrodes, delivering an electrical shock to restore normal rhythm.

The LifeVest WCD is prescribed for patients at risk of SCA, including those with a low ejection fraction (EJ), patients who have recently suffered a myocardial infarct (MI), those with a new diagnosis of heart failure (HF), and post-coronary revascularization patients. In a recent study that enrolled 2,302 post-MI patients in four countries, the LifeVest WCD, together with guideline directed medical therapy (GDMT) reduced total mortality by 36% in the first 90 days following MI, compared to GDMT alone. The study was presented American College of Cardiology (ACC) 67th annual scientific session, held during March 2018 in Orlando (FL, USA).

“In addition to the current best practices in medicine which includes GDMT, use of the LifeVest WCD can further reduce mortality in patients with a low EF,” said Kent Volosin, MD, vice president of medical and clinical affairs for ZOLL LifeVest. “The totality of clinical evidence supporting use of the WCD, along with guideline recommendations, underscores the need to evaluate all patients for sudden cardiac death risk and discuss WCD therapy with patients and their families through a shared decision-making approach.”

A companion online patient management system, The LifeVest Network, allows clinicians to monitor patient data downloaded from the LifeVest WCD, which can then be accessed online. The LifeVest Network also allows the physician to monitor patients efficiently and be notified of events recorded by the LifeVest device. The physician can log in and review patient information, or set up alerts and be notified when a patient has clinical information for review.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
MR Trolley
MR9002
New
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.